Sign in Subscribe
Cancer

Gastric Cancer Research Uncovers New Insights into Targeting Tumor-Associated Macrophages

Strategic Insights

— 1 min read

Research from a team of investigators at the Jian Yang Hospital of Traditional Chinese Medicine in Chengdu, Sichuan, has provided new insights into the progression and treatment of gastric cancer. According to the study, tumor-associated macrophages (TAMs) play a crucial role in the tumor immune microenvironment, and targeting these cells presents substantial therapeutic opportunities for patients with gastric cancer.

Key Takeaways:

  • Gastric cancer (GC) is the fifth most common malignant tumor worldwide, imposing significant public health burdens.
  • Systemic therapies for GC, such as chemotherapy, targeted therapy, and immunotherapy, have undergone significant advancements, but drug resistance remains a major challenge.
  • Tumor-associated macrophages (TAMs) are essential immunomodulators within the tumor immune microenvironment (TIME) of GC, providing novel therapeutic targets due to their capacity for plasticity in reaction to environmental signals.
  • TAMs create a complex network of communication with various immune and stromal cell types, thereby contributing to the immunosuppressive nature of the TME in GC.
  • The interactions between TAMs and tumor cells significantly influence the progression of GC, affecting tumor growth, metastasis, angiogenesis, and drug resistance.
  • Approaches such as TAM elimination, TAM repolarization, and CAR-M therapy have been validated in numerous studies as potential therapeutic strategies for targeting TAMs.
  • Targeting TAMs presents substantial therapeutic opportunities for patients with GC, offering innovative perspectives on GC treatment.

Statistics:

  • Gastric cancer is the fifth most common malignant tumor worldwide, accounting for approximately 10% of all cancer cases.
  • The five-year survival rate for gastric cancer is around 30-40%, with significant variation depending on the stage and type of cancer.
  • TAMs are estimated to be present in up to 85% of gastric cancer patients, with a significant association between TAM density and poor prognosis.
  • The most common types of TAMs in GC are M1 and M2 macrophages, with M2 macrophages being associated with tumor progression and poor outcomes.

Sources:

  • Wan, C. T., Deng, J., Zhu, Y., Wan, L., Xu, L. Y., Chen, Q. Y., ... & Huang, J. (2025). Targeting tumor-associated macrophages in gastric cancer progression and therapy: Insights from molecular mechanisms to therapeutic applications. Frontiers in Pharmacology, 16. doi: 10.3389/fphar.2025.1549694 (Free access available at https://doi-org.sdpl.idm.oclc.org/10.3389/fphar.2025.1549694)
  • NewsRx. (2025, July 2). Department of Gastroenterology Researchers Provide New Insights into Gastric Cancer (Targeting tumor-associated macrophages in gastric cancer progression and therapy: insights from molecular mechanisms to therapeutic applications). Immunotherapy Weekly, p 1105.

Read more